News:

Oct 17, 2018

Inovio’s DNA-Encoded Monoclonal Antibody (dMAb™) Platform Moves Ahead with Positive Data, Patents and Grants

Oct 15, 2018

Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies

Oct 08, 2018

Inovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb™) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies

See all news

Inovio is where
IMMUNO-INGENUITY is making the difference for patients with cancer and infectious diseases.

Learn more about our company

“At Inovio, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”

J. Joseph Kim, Ph.D.

President and CEO

Meet our team

Investor information

Review Inovio’s investor presentation highlighting our science, progress, and key upcoming milestones.

Download presentation

Inovio is focusing on transforming the prevention and treatment of cancer and infectious diseases.

Learn more about our focus

Product pipeline

Inovio has a robust pipeline of product candidates targeting cancer and infectious diseases, with several programs entering late stages of development.

Review our pipeline

Inovio's technology is IMMUNO-INGENUITY in action

The ASPIRE™ activation immunotherapy platform is generating best-in-class immune responses in the fight against cancer and infectious diseases.

Explore our technology